Last updated on November 2019

Randomized Open Label Clinical Study of the Targeted Therapy Palbociclib to Treat Metastatic Breast Cancer


Brief description of study

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.

Detailed Study Description

Subjects will be randomized into one of two treatment arms following minimum of 4 and maximum of 8 cycles of induction treatment with anti-HER2 therapy. Arm A subjects will receive the experimental therapy, palbociclib, in addition to their current anti-HER2 therapy and endocrine therapy. Arm B subjects will continue to receive the anti-HER2 therapy. It is expected that the addition of palbociclib to the first-line treatment of HER2 disease will delay the onset of therapeutic resistance and ultimately prolong the survival of patients with metastatic breast cancer. The study is designed to treat the subset of patients with HER2+ disease who are also hormone receptor positive (HR+). It is also expected that palbociclib will modulate the endocrine resistance in HER2+/HR+ disease and potentiate the benefits of anti-HER2 therapy. Lastly, the current study includes a comprehensive molecular characterization of the disease at study entrance which will allow us to investigate the benefits of palbociclib in subsets of HER2+/HR+ disease such as PIK3CA mutant.

Clinical Study Identifier: NCT02947685

Find a site near you

Start Over

Mayo Clinic, AZ

Phoenix, AZ United States
  Connect »

Ingalls Memorial Hospital

Harvey, IL United States
  Connect »

UCSF

San Francisco, CA United States
  Connect »

Memorial Healthcare System

Hollywood, FL United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

Florida Hospital

Orlando, FL United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Cancer Center of Kansas

Wichita, KS United States
  Connect »

Ochsner Medical Center Jefferson

New Orleans, LA United States
  Connect »

New England Cancer Specialists

Scarborough, ME United States
  Connect »

Anne Arundel Medical Center

Annapolis, MD United States
  Connect »

Lowell General Hospital

Lowell, MA United States
  Connect »

West Michigan Cancer Center

Grand Rapids, MI United States
  Connect »

Mayo Clinic, Rochester, MN

Rochester, MN United States
  Connect »

Hackensack Medical Center

Hackensack, NJ United States
  Connect »

New Mexico Cancer Care Alliance

Albuquerque, NM United States
  Connect »

Duke Cancer Institute

Durham, NC United States
  Connect »

Ohio State University

Columbus, OH United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

Lexington Medical Center

West Columbia, SC United States
  Connect »

MD Anderson

Houston, TX United States
  Connect »

Monash Health

Clayton, Australia
  Connect »

Icon Cancer Care

South Brisbane, Australia
  Connect »

Mater Cancer Care Centre

South Brisbane, Australia
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Centre Jean Perrin

Clermont-Ferrand, France
  Connect »

Centre CARIO-HPCA

Plerin Cedex, France
  Connect »

Gustave Roussy

Villejuif, France
  Connect »